Stay updated on ZUMA-2 Study Brexuca Clinical Trial

Sign up to get notified when there's something new on the ZUMA-2 Study Brexuca Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ZUMA-2 Study Brexuca Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A new publication entry was added to the Publications section, detailing a 2026 five-year follow-up study in ZUMA-2 with the full author list. This expands the study's referenced literature and acknowledges contributors.
    Difference
    0.0%
    Check dated 2026-05-04T08:57:18.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page’s site/interface “Revision” label was updated from v3.5.2 to v3.5.3, reflecting a tooling or release update rather than any modification to the trial record itself.
    Difference
    0.0%
    Check dated 2026-04-27T08:06:59.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Revision: v3.5.2 added; Revision: v3.5.0 removed.
    Difference
    0.0%
    Check dated 2026-04-20T05:13:29.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    Added Blood 2026 publication citation for ZUMA-2 cohort 3 and removed Blood 2025 ahead-of-print citation in Publications.
    Difference
    0.0%
    Check dated 2026-04-05T19:40:38.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added author/investigator names for the ZUMA-2 study publication. Introduced IPD sharing details, including URL, access criteria, time frame, and related documents (SAP, Study Protocol).
    Difference
    0.7%
    Check dated 2026-03-22T11:11:48.000Z thumbnail image
  7. Check
    55 days ago
    Change Detected
    Summary
    Publication citation removed from the Publications section: Darnell EP, Gallagher KME, Kanska J, Scarfo I, Balderrama-Gutierrez G, Berger TR, Budka J, Bozym DJ, Huang T, Shen R, Leick MB, Maus MV. Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026;10(4):1023-1034.
    Difference
    0.0%
    Check dated 2026-03-15T06:29:47.000Z thumbnail image

Stay in the know with updates to ZUMA-2 Study Brexuca Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ZUMA-2 Study Brexuca Clinical Trial page.